Does Counting Adult Tissue Stem Cells Have a Human Impact?

by Asymmetrex on March 30, 2016

Does Counting Adult Tissue Stem Cells Have a Human Impact?

Asymmetrex’s 3-month campaign to increase awareness of the adult tissue stem cell counting problem has focused on how its AlphaSTEM technology solution could impact research and clinical practice.  Now, the final post in the series answers the question, “Does counting adult tissue stem cells have a human impact?”

Today on RegMedNet, Asymmetrex posted its final comment in a 6-expose series to increase awareness among the international regenerative medicine community of the importance of counting adult tissue stem cells for several different areas of stem cell medicine, drug development, and tissue stem cell research.  The final post emphasizes the immediate human impact of adoption of the company’s new AlphaSTEM technology.  As highlighted on the Asymmetrex website this week, one of the most significant impacts of counting adult tissue stem cells would be immediately starting to reduce the loss and anguish currently endured by families of children treated for leukemia with cord blood samples that may have insufficient blood stem cells for their survival.  Now, the simple act of counting the number of blood stem cells in these samples would make the deaths of many children with this dreaded disease avoidable; and it would free waiting families from the distress and fear that their child might be fated to die because before it was not possible to tell if a cord blood sample had sufficient stem cells. Find more information on the greater human impact of adult tissue stem cell counting on the RegMedNet site.

As its founder and current Director, Dr. Sherley leads Asymmetrex with a mission of advancing emerging adult stem cell tissue technologies to applications in clinical drug discovery and cellular medicine. Asymmetrex is the developer and holder of a rich portfolio of recently issued patents for biotechnologies for the quantification and production of human adult tissue stem cells.

 

 

 

Read More
AsymmetrexDoes Counting Adult Tissue Stem Cells Have a Human Impact?

Saving More Lives from Leukemia by Counting Blood Stem Cells

by Asymmetrex on March 28, 2016

“Leukemia” is a dreaded thing to be told after bringing your child to the doctor because she has become inexplicably tired with a cold that just won’t go away. In the U.S., every year, more than 5000 families hear this cancer name. Thanks to many years of research and clinical investigation, though the treatments are harsh with long-term debilitating side effects, overall survival from leukemia in children and young adults is now about 90%. This high rate of survival is quite an achievement, reflecting the shared efforts of nurses, doctors, counselors, communities, families, and patients. But that remaining lost 10% represents more than 500 real families, each year, destined to face the death of their child. Though medical science and technology may have given the best care available, many of these deaths are not preventable within the present state of knowledge. However, there may be a significant subset of these children for whom a new technology for counting blood stem cells could make a difference.

Many children with leukemia will eventually require a blood stem cell transplant to be cured of their cancer. This need is especially true for a type of leukemia called acute myelogenous leukemia (AML). Essentially all of the nearly 1150 children who present each year in the U.S. with AML will undergo a transplant of either bone marrow or umbilical cord blood, which contain blood stem cells that are crucial for their survival after treatments designed to kill all leukemia cells. These treatments also kill their own blood stem cells that are required for life.

It is in the case of cord blood transplants that counting blood stem cells could ease a lot of anguish and save more children from leukemia. In 2013, there were a reported 931 cord blood transplants performed in the U.S, including 317 for AML, with most being used to treat children. About 10-20% of these transplants failed, resulting in the deaths of 30-60 children with AML. They failed because of insufficient blood stem cells. Cord blood samples have fewer blood stem cells than bone marrow, which has much scarcer donors but a lower failure rate (1-5%). Unfortunately, previously, there has been no way to predict which transplants would fail due to insufficient blood stem cells, because there was no means to count the number of blood stem cells before the transplant.

So today, throughout the country, and the world for that matter, each year hundreds of very sick children wait with their families for more than two months with dread and deep anguish to find out if their cord blood transplant grafted successfully. The simple action of counting the number of blood stem cells in cord blood samples before using them would avoid deaths from inadequate transplants. Not only would this intervention save the lives of 30-60 children, it would eliminate a major source of distress for hundreds of children, their families, and their medical teams.

The current estimate of cord blood samples in the world is 700,000! However, only about 10% may be considered useful, because their total cell count (“TNC”) is below the number currently thought to indicate adequate blood stem cells, which are present in very low amounts. However, the number of blood stem cells present has no established predictive relationship to TNC. Clearly, TNC is in error 10-20% of the time for there being sufficient blood stem cells. All things being equal, it may have a similar error for indicating insufficient blood stem cells. In any case, with a new blood stem cell counting technology available, the clear mandate is to use it to count blood stem cells directly in any cord blood sample that might be used to save a child, or an adult, with leukemia. The same mandate applies to other sources of blood stem cells for transplant treatments. Though transplants with bone marrow or circulating blood that contains blood stem cells have much lower failure rates caused by insufficient blood stem cells, their greater number of transplant treatments (20,000 per year in the U.S.; 68,000 worldwide) result in a number of annual deaths comparable to the number estimated for cord blood transplants.

Read More
AsymmetrexSaving More Lives from Leukemia by Counting Blood Stem Cells

Webinar: Technology for Counting Adult Tissue Stem Cells

by Asymmetrex on March 23, 2016

Webinar: A first technology for counting adult tissue stem cells for applications in regenerative medicine and drug development

Since the first discovery of adult tissue stem cells, it has been impossible to count them. This conundrum persists because neither morphological nor molecular properties have been defined that distinguish tissue stem cells from more abundant committed progenitor cells. This webinar introduced AlphaSTEM, a first-in-class technology with the capability of counting homeostatic stem cells in complex research and therapeutic cell preparations from many different human tissues. The predicted impact of the AlphaSTEM stem cell counting technology on stem cell research, umbilical cord blood bank practice, hematopoietic stem cell transplantation therapies, gene-editing therapeutics, and drug candidate evaluations was considered.  Listen to the webinar on demand now.

What will you learn?

  • The nature of the adult tissue stem cell counting problem
  • How the AlphaSTEM stem cell counting technology works
  • How stem cell counting will impact tissue stem cell research
  • How the determination of “stem cell dose”, for the first time, will impact stem cell transplantation medicine, gene-editing therapeutics, and regenerative medicine research in general
  • How the ability to count tissue stem cells has already enabled assays that identify drug candidates that affect tissue stem cells, negatively, positively, or both

Who may this interest?

  • Research stem cell biologists, university and industry
  • Preclinical drug candidate evaluation CROs
  • Pharmaceutical companies (toxicologists, pharmacovigilance executives)
  • Hematopoietic stem cell transplantation physicians
  • Umbilical cord blood bank directors
  • Gene-editing therapeutic companies
Read More
AsymmetrexWebinar: Technology for Counting Adult Tissue Stem Cells

How AlphaSTEM Technology is used to Count Adult Tissue Stem Cells

by Asymmetrex on March 17, 2016

On March 22, Boston stem cell medicine technology start-up Asymmetrex will present a free, public, online webinar with the goal of discussing how it developed a stem cell technology that has been needed since the beginnings of stem cell biology. Hosted by RegMedNet, a London-based social media network for regenerative medicine professionals, the webinar will provide a first public discussion forum on the company’s new AlphaSTEM technology for counting adult tissue stem cells for the first time.

In a Scheduled March 22 RegMedNet Webinar, Asymmetrex Discusses the Strategy for How AlphaSTEM Technology is used to Count Adult Tissue Stem Cells

BOSTON, MA (PRWEB) MARCH 17, 2016

Asymmetrex, a stem cell medicine technology start-up company headquartered in Boston, began a social media campaign in late 2015 to increase awareness of a long-standing unmet need in stem cell research and stem cell biomedicine. Since the beginnings of stem cell biology in the 1950s, it has not been possible to count adult tissue stem cells. The problem stems from difficulty discovering biomarkers that recognize tissue stem cells, but not their more abundant relatives called committed progenitor cells.

The company has a lot of interest in rekindling attention to this stem cell counting problem, which has existed for so long that some stem cell investigators are unaware of it, some try to work as best they can while knowing it, or some ignore it. Each of these responses undermines the potential of stem cell research and stem cell medicine progress. By providing a solution, Asymmetrex has the potential to improve the quality of stem cell research and greatly accelerate progress in stem cell-based regenerative medicine, including drug development and gene therapies.

Both the educational campaign and the webinar are hosted by the UK social media network RegMedNet. In anticipation of the webinar, RegMedNet posted an audio interview with Asymmetrex Director James Sherley, M.D., Ph.D. on March 14. During the campaign, Director Sherley has posted discussions that describe how the ability to count adult tissue stem cells will transform a wide range of practices in stem cell research, regenerative medicine, drug development, and even environmental health science. Suggested transformations include early identification of drug candidates that would cause organ and tissue failure later in more costly animal studies and clinical trials; evaluation of the stem cell sufficiency of cord blood bank donor samples; determination of the dose of stem cells in transplantation treatments; and increased efficiency and long-term efficacy in gene therapies and gene-editing therapeutics.

In the RegMedNet audio interview, Sherley related the scientific history that culminated in the new AlphaSTEM technology for counting adult tissue stem cells. A key partner in the development of the technology is the statistical modeling and computer simulation leader AlphaSTAR Corp. The two companies are now seeking venture funding to spin out a new company, AlphaSTEM Co., that will further develop and market the new counting technology.

In the upcoming March 22 webinar, Asymmetrex will continue its aim of introducing the attributes of the new technology to the stem cell biology, drug development, regenerative medicine, gene therapy, and gene-editing therapeutics communities. Director Sherley will present the essential elements of the AlphaSTEM method and the results of several experimental validations. Significant time will be allotted for discussion with webinar attendees. The partnering companies are particularly interested in this initial public comment.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexHow AlphaSTEM Technology is used to Count Adult Tissue Stem Cells

Why Gene Therapy Depends on Counting Stem Cells

by Asymmetrex on March 9, 2016

In a RegMedNet post today (March 9, 2016), Asymmetrex explains that, although much attention is given to molecular genetics advances in the efficiency and integrity of new technologies for gene therapy, failure to count tissue stem cells is likely to limit future treatment success. Sufficient genetic engineering and transplantation of targeted tissue stem cells, like blood hematopoietic stem cells, are crucial for effective gene therapy.  Genetic engineering and gene-editing of rare stem cells face significant competition from abundant committed progenitor cells that can only give short-term treatment.  So, the desired long-term treatment depends heavily on stem cell number that is currently an unknown in gene replacement and gene-editing clinical trials.  In addition to today’s post, Asymmetrex’s founder and director, James L. Sherley, will give a presentation at 4:30 pm to relate how Asymmetrex’s new AlphaSTEM technology for counting adult tissue stem cells can address this important unmet need. The presentation is an invited talk at the Clinical Trials Supply New England 2016 conference taking place in the Revere Hotel in downtown Boston.

Read More
AsymmetrexWhy Gene Therapy Depends on Counting Stem Cells

Asymmetrex Intensifies Value of Counting Adult Stem Cells

by Asymmetrex on March 2, 2016

In Upcoming Webinar and Conferences, Asymmetrex Will Intensify Education on Counting Adult Tissue Stem Cells For Regenerative Medicine and Drug Development

As 2015 drew to a close, stem cell medicine biotechnology start-up company Asymmetrex began an effort to educate the pharmaceutical and regenerative medicine industries on the value of counting adult tissue stem cells. The company is now intensifying this effort with a newly developed free webinar and two scheduled conference presentations to clinical trial developers and the rapidly growing gene-editing therapeutics community.

BOSTON, MA (PRWEB) MARCH 02, 2016

As 2015 drew to a close, stem cell medicine biotechnology start-up company Asymmetrex began an effort to educate the pharmaceutical and regenerative medicine industries on the value of counting adult tissue stem cells. The company is now intensifying this effort with a newly developed free webinar and two scheduled conference presentations to clinical trial developers and the rapidly growing gene-editing therapeutics community.

“Although medicine, science, and technology professionals value innovation highly, they are also trained to be skeptical of it. Myself included. Skepticism runs particularly high when an innovation is not just a better mousetrap, but the first mousetrap. Getting people to try it is even more challenging, if catching mice was previously thought impossible; and might expose a house full of them.”

That’s how James Sherley, Director of Asymmetrex, says he thinks about the challenge his company now faces with gaining acceptance and adoption of its new AlphaSTEM technology for counting adult tissue stem cells. For more than a half century, since its beginnings, the field of stem cell biology has had no method available for counting adult tissue stem cells, though not for lack of trying. However, with the best-described biomarkers found to lack the degree of specificity required for use in counting, stem cell biology and the related translational field of regeneration medicine pretty much gave up on the quest. These fields have been trying to get along without it, in many cases in a state of denial about the negative consequences of trying to do so.

Sherley calls adult tissue stem cell counting “a hidden unmet need” in stem cell research and many related biomedical fields, including drug development, stem cell transplantation medicine, regenerative medicine clinical investigation, gene therapy, and the newly emerging field of gene-editing therapeutics. To provide increased education on these understated or unrecognized deficiencies, starting in January of this year, Asymmetrex has sponsored bi-weekly blogs on the regenerative medicine professionals’ social media network RegMedNet. For example, the blogs highlight fundamental deficiencies in ongoing regenerative medicine trials in which the stem cell number in transplanted treatment preparations is unknown. Without knowing stem cell number, and thereby stem cell dose, how can outcomes be interpreted from one trial to the next?

Asymmetrex is now marketing its AlphaSTEM technology as the long-needed solution to the stem cell counting and stem cell dosing problems. The company is focused on developing interest among executives in pharmaceutical companies, regenerative medicine companies, and gene-editing therapeutics companies. Asymmetrex is also courting contract research organizations, which provide preclinical cell culture assays to pharmaceutical companies, as a strategy to accelerate the introduction of the value of AlphaSTEM technology to their clients for identifying stem cell-toxic drugs earlier during drug development.

Sherley says the key to launching AlphaSTEM technology onward to future sales is industry visibility, education, and increasing prospective client contacts. Over the next several months the company has several scheduled events to boost AlphaSTEM visibility and education. These include a March 9 presentation at Clinical Trial Supply New England 2016, a March 22 free RegMedNet webinar, continued bi-weekly educational blog posts and a to-be-announced online audio interview with Director Sherley on RegMedNet, and a presentation at the 2016 Precision Medicine Symposium –RNAi/MicroRNAs to Stem Cells & Genome Editing on May 4-5.

Whether 2016 will be the year of adult tissue stem cell counting remains to be seen. Sherley says, “If not this year, then the next; but it is inevitable.” He says that the first to adopt the technology will realize a significant advantage over their competitors, whether between academic researchers at the bench, rival pharmaceutical companies, clinical investigators at the bedside, of physicians treating patients with approved stem cell therapies. “It’s too important in human biology not to make a difference.”

About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexAsymmetrex Intensifies Value of Counting Adult Stem Cells

Asymmetrex’s Call to Save Money, Patients and Time

by Asymmetrex on February 24, 2016

Today in its company sponsored RegMedNet post, Asymmetrex highlights how its AlphaSTEM technology for counting adult tissue stem cells has potential for high impact in the pharmaceutical industry.  Regenerative medicine also encompasses the application of stem cell fundamentals to identify traditional small molecules and biologics drug candidates to treat disorders of aging, induce or accelerate healing of injuries, as well as treat more familiar diseases and disorders.  By counting tissue stem cells for the first time, Asymmetrex’s AlphaSTEM technology can be used to identify drug candidates that cause intolerable organ and tissue failure because of toxicity against tissue stem cells.  Currently, such failed drugs are not discovered until expensive animal studies or clinical trials with volunteer research subjects and patients.  Such failures for safety are estimated to cost the U.S. pharmaceutical industry $4-5 billion each year.  By screening out stem cell-toxic drug candidates earlier and cheaper, adopting AlphaSTEM technology is projected to save major pharmaceutical companies hundreds for millions of dollars each year, while increasing overall drug safety, and accelerating the identification of effective drugs.

Read More
AsymmetrexAsymmetrex’s Call to Save Money, Patients and Time

Asymmetrex Leading the Dosing Elephant Out of Regenerative Medicine

by Asymmetrex on February 11, 2016

Today Asymmetrex continues its efforts to bring more attention to the long-standing need for tissue stem cell counting in regenerative medicine.  In a post on RegMedNet, the company contrasts the quantitative dosing precision required for pharmaceutical drug trials to the complete vacuum of quantitative dosing for tissue stem cells in regenerative medicine trials.  Asymmetrex invites regenerative medicine companies and physicians’ trials group to evaluate the company’s new AlphaSTEM technology for counting tissue stem cells.  Asymmetrex predicts that adoption of the technology in 2016 would have a major impact on the quality of stem cell medicine clinical trials.

Read More
AsymmetrexAsymmetrex Leading the Dosing Elephant Out of Regenerative Medicine

Asymmetrex Ready to Do a Number for HSC Transplantation Therapies

by Asymmetrex on February 8, 2016

Asymmetrex Ready to Do a Number for Hematopoietic Stem Cell Transplantation Therapies

To prepare the field of regenerative medicine for its AlphaSTEM stem cell counting technology, Asymmetrex makes good on its earlier promise to post on the RegMedNet Industry Developments page an expose on the vexing, but silent, nature of the HSC counting problem in HSCT medicine. Because no earlier technology for counting HSCs has been available, HSCT is the one field of medicine that is unable to determine the dose of its most important medicine, HSCs. Asymmetrex relates the clinical implications of this long-standing shortcoming, in particular how it impacts dire HSCT with umbilical cord blood. To learn more visit RegMedNet.

Read More
AsymmetrexAsymmetrex Ready to Do a Number for HSC Transplantation Therapies

Asymmetrex Supports UK RegMedNet with Sponsorship

by Asymmetrex on February 8, 2016

Asymmetrex Supports UK RegMedNet with Sponsorship for Education on the Importance of Counting Adult Tissue Stem Cells in Regenerative Medicine Practice

Stem cell medicine biotechnology company Asymmetrex is the most recently invited company sponsor to support UK-based RegMedNet, an international network developed to unite the members of the diverse community of regenerative medicine worldwide. In the coming months, the company will focus its sponsorship on informing RegMedNet members of the advantages and value of its new technologies for counting adult tissue stem cells for many applications in regenerative medicine.

In its first post after joining UK RegMedNet as an invited company sponsor, stem cell biomedicine technology company Asymmetrex, now headquartered in Boston, Massachusetts in the U.S, focused on distinguishing regenerative medicine (“RegMed”) companies from other biotechnology enterprises. Generally, RegMed companies do not fit well within common therapeutic and biotechnology classifications as “product” companies or as “platform technology” companies. Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., suggests that instead the new classification, “stem cell fundamentals” companies, better describes the unifying motivation of RegMed companies. RegMed companies “seek to develop one or more fundamental biological properties of stem cells to address important unmet needs in medicine.”

The stem cell fundamental that motivates the business of Asymmetrex is asymmetric self-renewal. This is the biological process by which adult tissue stem cells divide to make simultaneously both unchanged new stem cells and sister cells committed to change to replenish or repair the organs and tissues of the body. Applying its unique expertise in asymmetric self-renewal research, Asymmetrex has developed patented technologies for addressing two important challenges in regenerative medicine, producing adult tissue stem cells and counting them. The goal of the company’s RegMedNet sponsorship is to better inform RegMedNet members of the vital advances that introducing adult tissue stem cell counting into their research and clinical practice would make.

No one would argue that knowing the number of stem cells present in any process involving them would not be important and valuable. Yet, currently, in basic research labs, clinical research labs, medical centers, and hospitals, worldwide, all relevant practices proceed without knowing tissue stem cell number, because this information has been unobtainable. Regenerative medicine battles forth with this same blind spot that stem cell biology has endured for more than half a century.

Asymmetrex has developed innovative technologies to end the non-quantitative state of regenerative medicine. These include new biomarkers with increased specificity for identifying adult tissue stem cells and a new computer simulation technology that is able to count many different types of human adult tissue stem cells. These technologies are an obvious set of new tools for accelerating advances in regenerative medicine. They also have valuable applications in other areas of biomedicine that are impacted by tissue stem cells, like drug development and environmental toxicology.

Asymmetrex plans to work with RegMedNet towards achieving a sea change in how its regenerative medicine community thinks about adult tissue stem cell number. The company’s technologies can demonstrate that in many settings it is now possible to count adult tissue stem cells, for the first time, to great advantage and value. Moving the fields of stem cell biology and regenerative medicine rapidly to a new standard of quantitative practice may take a bit of network chaos first. In the coming months, Asymmetrex will attempt to introduce just such a butterfly effect through RegMedNet to the broader regenerative medicine community.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexAsymmetrex Supports UK RegMedNet with Sponsorship